Expression of endothelin 1 in rat random-pattern skin flaps treated with topical nifedipine

Steven Ross Mobley, Marilyn K Glassberg Csete, Anne Luebke, Chad A. Perlyn, Richard E. Davis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To evaluate the relative tissue concentrations of the endogenous vasoactive peptide endothelin 1 (ET-1) in random-pattern skin flaps (RPSF) treated with either topical anti-ischemic drug therapy (nifedipine) or placebo. Design: Prospective, randomized, placebo-controlled therapeutic trial. Subjects: Adult male Sprague-Dawley rats. Intervention: Experimental subjects underwent caudally based RPSFs using the modified McFarlane technique. Subjects received either topical anti-ischemic drug therapy (nifedipine; n=6) or inert carrier ointment (placebo; n=6). Treatment was initiated immediately following flap closure and continued every 6 hours for 5 days. At the end of the treatment period, the animals were killed and the concentration of ET-1 was determined using enzyme-linked immunosorbent assay. Representative tissues from nifedipine-and placebo-treated skin flaps were also analyzed for ET-1 using immunohistochemical stains. Results: The ET-1 levels in the distal (necrotic) flap segments were increased by 4.53 pg/mL over baseline (nonnecrotic) flaps in the placebo-treated animals and decreased by 4.70 pg/mL below baseline in the nifedipinetreated group (P=.03). Conclusions: The correlation between tissue levels of ET-1 and the severity of tissue necrosis suggests that ET-1 may play a pivotal role in ischemic injury of RPSFs. Moreover, treatment with topical nifedipine may antagonize the vasoconstrictive effects of ET-1. Although immunohistochemical analysis revealed ET-1 staining within the flap microvasculature, no quantitative differences were detected between the nifedipine-and placebo-treated flaps. Further studies are needed to define the role of ET-1 in RPSF necrosis.

Original languageEnglish
Pages (from-to)78-82
Number of pages5
JournalArchives of Facial Plastic Surgery
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Endothelin-1
Nifedipine
Skin
Placebos
Necrosis
Drug Therapy
Therapeutics
Ointments
Microvessels
Sprague Dawley Rats
Coloring Agents
Enzyme-Linked Immunosorbent Assay
Staining and Labeling
Peptides
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery

Cite this

Expression of endothelin 1 in rat random-pattern skin flaps treated with topical nifedipine. / Mobley, Steven Ross; Glassberg Csete, Marilyn K; Luebke, Anne; Perlyn, Chad A.; Davis, Richard E.

In: Archives of Facial Plastic Surgery, Vol. 5, No. 1, 01.01.2003, p. 78-82.

Research output: Contribution to journalArticle

Mobley, Steven Ross ; Glassberg Csete, Marilyn K ; Luebke, Anne ; Perlyn, Chad A. ; Davis, Richard E. / Expression of endothelin 1 in rat random-pattern skin flaps treated with topical nifedipine. In: Archives of Facial Plastic Surgery. 2003 ; Vol. 5, No. 1. pp. 78-82.
@article{d79e6aa9292b47f1a9341b8d6a0deade,
title = "Expression of endothelin 1 in rat random-pattern skin flaps treated with topical nifedipine",
abstract = "Objective: To evaluate the relative tissue concentrations of the endogenous vasoactive peptide endothelin 1 (ET-1) in random-pattern skin flaps (RPSF) treated with either topical anti-ischemic drug therapy (nifedipine) or placebo. Design: Prospective, randomized, placebo-controlled therapeutic trial. Subjects: Adult male Sprague-Dawley rats. Intervention: Experimental subjects underwent caudally based RPSFs using the modified McFarlane technique. Subjects received either topical anti-ischemic drug therapy (nifedipine; n=6) or inert carrier ointment (placebo; n=6). Treatment was initiated immediately following flap closure and continued every 6 hours for 5 days. At the end of the treatment period, the animals were killed and the concentration of ET-1 was determined using enzyme-linked immunosorbent assay. Representative tissues from nifedipine-and placebo-treated skin flaps were also analyzed for ET-1 using immunohistochemical stains. Results: The ET-1 levels in the distal (necrotic) flap segments were increased by 4.53 pg/mL over baseline (nonnecrotic) flaps in the placebo-treated animals and decreased by 4.70 pg/mL below baseline in the nifedipinetreated group (P=.03). Conclusions: The correlation between tissue levels of ET-1 and the severity of tissue necrosis suggests that ET-1 may play a pivotal role in ischemic injury of RPSFs. Moreover, treatment with topical nifedipine may antagonize the vasoconstrictive effects of ET-1. Although immunohistochemical analysis revealed ET-1 staining within the flap microvasculature, no quantitative differences were detected between the nifedipine-and placebo-treated flaps. Further studies are needed to define the role of ET-1 in RPSF necrosis.",
author = "Mobley, {Steven Ross} and {Glassberg Csete}, {Marilyn K} and Anne Luebke and Perlyn, {Chad A.} and Davis, {Richard E.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1001/archfaci.5.1.78",
language = "English",
volume = "5",
pages = "78--82",
journal = "JAMA Facial Plastic Surgery",
issn = "2168-6076",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Expression of endothelin 1 in rat random-pattern skin flaps treated with topical nifedipine

AU - Mobley, Steven Ross

AU - Glassberg Csete, Marilyn K

AU - Luebke, Anne

AU - Perlyn, Chad A.

AU - Davis, Richard E.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objective: To evaluate the relative tissue concentrations of the endogenous vasoactive peptide endothelin 1 (ET-1) in random-pattern skin flaps (RPSF) treated with either topical anti-ischemic drug therapy (nifedipine) or placebo. Design: Prospective, randomized, placebo-controlled therapeutic trial. Subjects: Adult male Sprague-Dawley rats. Intervention: Experimental subjects underwent caudally based RPSFs using the modified McFarlane technique. Subjects received either topical anti-ischemic drug therapy (nifedipine; n=6) or inert carrier ointment (placebo; n=6). Treatment was initiated immediately following flap closure and continued every 6 hours for 5 days. At the end of the treatment period, the animals were killed and the concentration of ET-1 was determined using enzyme-linked immunosorbent assay. Representative tissues from nifedipine-and placebo-treated skin flaps were also analyzed for ET-1 using immunohistochemical stains. Results: The ET-1 levels in the distal (necrotic) flap segments were increased by 4.53 pg/mL over baseline (nonnecrotic) flaps in the placebo-treated animals and decreased by 4.70 pg/mL below baseline in the nifedipinetreated group (P=.03). Conclusions: The correlation between tissue levels of ET-1 and the severity of tissue necrosis suggests that ET-1 may play a pivotal role in ischemic injury of RPSFs. Moreover, treatment with topical nifedipine may antagonize the vasoconstrictive effects of ET-1. Although immunohistochemical analysis revealed ET-1 staining within the flap microvasculature, no quantitative differences were detected between the nifedipine-and placebo-treated flaps. Further studies are needed to define the role of ET-1 in RPSF necrosis.

AB - Objective: To evaluate the relative tissue concentrations of the endogenous vasoactive peptide endothelin 1 (ET-1) in random-pattern skin flaps (RPSF) treated with either topical anti-ischemic drug therapy (nifedipine) or placebo. Design: Prospective, randomized, placebo-controlled therapeutic trial. Subjects: Adult male Sprague-Dawley rats. Intervention: Experimental subjects underwent caudally based RPSFs using the modified McFarlane technique. Subjects received either topical anti-ischemic drug therapy (nifedipine; n=6) or inert carrier ointment (placebo; n=6). Treatment was initiated immediately following flap closure and continued every 6 hours for 5 days. At the end of the treatment period, the animals were killed and the concentration of ET-1 was determined using enzyme-linked immunosorbent assay. Representative tissues from nifedipine-and placebo-treated skin flaps were also analyzed for ET-1 using immunohistochemical stains. Results: The ET-1 levels in the distal (necrotic) flap segments were increased by 4.53 pg/mL over baseline (nonnecrotic) flaps in the placebo-treated animals and decreased by 4.70 pg/mL below baseline in the nifedipinetreated group (P=.03). Conclusions: The correlation between tissue levels of ET-1 and the severity of tissue necrosis suggests that ET-1 may play a pivotal role in ischemic injury of RPSFs. Moreover, treatment with topical nifedipine may antagonize the vasoconstrictive effects of ET-1. Although immunohistochemical analysis revealed ET-1 staining within the flap microvasculature, no quantitative differences were detected between the nifedipine-and placebo-treated flaps. Further studies are needed to define the role of ET-1 in RPSF necrosis.

UR - http://www.scopus.com/inward/record.url?scp=0038728817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038728817&partnerID=8YFLogxK

U2 - 10.1001/archfaci.5.1.78

DO - 10.1001/archfaci.5.1.78

M3 - Article

C2 - 12533145

AN - SCOPUS:0038728817

VL - 5

SP - 78

EP - 82

JO - JAMA Facial Plastic Surgery

JF - JAMA Facial Plastic Surgery

SN - 2168-6076

IS - 1

ER -